Reaction

Painful Respiration reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,380 reports · 50 co-occurring drugs

As of the last recalculation, Painful Respiration appears in 2,380 FAERS reports alongside 50 co-occurring drug terms. The strongest observed disproportionality signal is TOBRAMYCIN SOLUTION (PRR 18.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Tobramycin Solution	25	18.4	18.4
Tobramycin Sulfate	25	17.8	17.9
Theophylline Anhydrous	22	15.7	15.7
Theophylline	20	15.3	15.4
Drospirenone And Ethinyl Estradiol	66	13.4	13.4
Tiotropium Bromide Inhalation Spray	15	11.8	11.8
Mercaptopurine	21	10.7	10.7
Tobramycin	29	10.7	10.7
Mometasone Furoate	49	10.5	10.5
Candesartan	40	10.0	10.0
Ciclesonide	15	9.7	9.7
Docusate Sodium 100Mg	23	8.5	8.5
Ipratropium Bromide	34	8.4	8.4
0Xygen	46	8.3	8.3
Oxygen	46	8.3	8.3
Terazosin Hydrochloride	8	7.9	7.9
Febuxostat Tablets 40 Mg	9	7.8	7.8
Febuxostat Tablets 80 Mg	9	7.8	7.8
Fluticasone Propionate And Salmeterol Xinafoate	52	7.7	7.7
Treprostinil	105	7.6	7.6
Moxifloxacin Hydrochloride	17	7.4	7.4
Pirfenidone	28	6.1	6.1
Riociguat	22	5.9	5.9
Mepolizumab	32	5.7	5.7
Omalizumab	54	5.6	5.6
Iron Sucrose	6	5.5	5.5
Tiotropium Bromide	82	5.4	5.4
Pertuzumab	16	5.2	5.2
Ocrelizumab	36	5.1	5.1
Sildenafil	33	5.0	5.0
Belimumab	18	5.0	5.0
Umeclidinium	5	4.9	4.9
Epoprostenol	7	4.7	4.7
Macitentan	35	4.5	4.5
Ambrisentan	62	4.4	4.4
Ado-Trastuzumab Emtansine	4	4.2	4.2
Fluticasone Propionate And Salmeterol	18	3.8	3.8
Regorafenib	5	3.8	3.8
Umeclidinium Bromide And Vilanterol Trifenatate	7	3.7	3.7
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	17	3.6	3.6
Oseltamivir Phosphate	10	3.6	3.6
Elexacaftor, Tezacaftor, And Ivacaftor	5	3.5	3.5
Nintedanib	12	3.4	3.4
Bosentan	19	3.3	3.3
Diclofenac Potassium, Film Coated	3	3.1	3.1
Diclofenac Potassium Tablets	3	3.1	3.1
Lumacaftor And Ivacaftor	3	3.1	3.1
Palivizumab	5	2.9	2.9
Dornase Alfa	6	2.7	2.7
Sarilumab	7	2.3	2.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.